BS01 in Patients With Retinitis Pigmentosa

Last updated: May 1, 2023
Sponsor: Bionic Sight LLC
Overall Status: Active - Recruiting

Phase

1/2

Condition

Eye Disorders/infections

Posterior Uveitis

Retinitis Pigmentosa

Treatment

BS01

Clinical Study ID

NCT04278131
BS01-RP-001
  • Ages > 18
  • All Genders

Study Summary

Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Confirmed diagnosis of retinitis pigmentosa
  • Bare light perception in at least one eye

Exclusion

Exclusion Criteria:

  • Prior receipt of any AAV gene therapy product
  • Large amplitude nystagmus

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: BS01
Phase: 1/2
Study Start date:
February 06, 2020
Estimated Completion Date:
December 30, 2029

Connect with a study center

  • OCLI

    New York, New York 11572
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.